Floatz logo

EF-5

Ovarian Sarcoma

National Cancer Institute (NCI)Small moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

1 Active assets in the Ovarian Sarcoma cohort.

Asset / SponsorPhaseRating
Ziv-Aflibercept
National Cancer Institute (NCI)
Phase 2B
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Angiotensin-(1-7)
Wake Forest University Health Sciences
Phase 2CCC
mk-2206
National Cancer Institute (NCI)
Phase 2CCC
Gdc-0449
National Cancer Institute (NCI)
Phase 1/2CCC

View all 14 →

Same molecule, other indications

EF-5 is also rated in:

cervical cancerDormant
CC
Indicative ·
47 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
Stage I Ovarian Epithelial CancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →